menu
    • menu

    Company profile for Neurim Pharmaceuticals

    NEW Drugs in Dev: 4
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Neurim Pharmaceuticals is a neuroscience drug discovery and development company dedicated to creating drugs for brain restoration and reinforcement, with a focus on the central nervous system. Boasting a proven track record in drug development and commercialization, Neurim's initial products, Circadin® and Slenyto®, are utilized in over 40 countries across 5 continents.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Neurim PharmaceuticalsIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    HaBarzel 27, Tel Aviv 69710
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://neurim.com/
    Linkedin
    Linkedin
    https://il.linkedin.com/company/neurim-pharmaceuticals-ltd
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kye Pharma Licenses SLENYTO from Neurim for Canadian Market
    Kye Pharma Licenses SLENYTO from Neurim for Canadian Market

    13 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kye-pharmaceuticals-announces-licensing-and-distribution-agreement-with-neurim-pharmaceuticals-for-slenyto-in-canada-302658041.html

    PR NEWSWIRE
    13 Jan 2026
    Share Share
    Health Canada Approves Slenyto for Insomnia in Autistic Childrene
    Health Canada Approves Slenyto for Insomnia in Autistic Childrene

    10 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/health-canada-approves-slenyto---extended-release-melatonin-formulation---as-a-prescription-drug-for-insomnia-in-children-with-autism-spectrum-disorder-and-smith-magenis-syndrome-302552663.html

    PR NEWSWIRE
    10 Sep 2025
    Share Share
    Neurim Pharmaceuticals gets EU approval for pediatric melatonin
    Neurim Pharmaceuticals gets EU approval for pediatric melatonin

    26 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurim-pharmaceuticals-receives-european-marketing-authorization-for-pediatric-prolonged-release-melatonin-slenyto-for-the-treatment-of-insomnia-in-children-with-attention-deficit-hyperactivity-disorder-adhd-302411183.html

    PR NEWSWIRE
    26 Mar 2025
    Share Share
    EMA Committee Recommends Slenyto For Insomnia In Children With NGDs
    EMA Committee Recommends Slenyto For Insomnia In Children With NGDs

    31 Jul 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=171607&sid=2

    PHARMABIZ
    31 Jul 2024
    Share Share
    Neurim Gets CHMP Opinion On SLENYTO For Insomnia In Children With NGDs
    Neurim Gets CHMP Opinion On SLENYTO For Insomnia In Children With NGDs

    30 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurim-pharmaceuticals-receives-positive-chmp-opinion-on-slenyto-pediatric-prolonged-release-melatonin-for-the-treatment-of-insomnia-in-children-with-neurogenetic-disorders-ngds-302209423.html

    PR NEWSWIRE
    30 Jul 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search